Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Faraz Kerendi

Thoracic Surgery (Cardiothoracic Vascular Surgery) Austin, TX Medical Doctor

NPI 1376727842 CMS profile 289638

1010 W 40Th St, Austin, TX 78756

Open in the dashboard

General payments

$906,136

1,199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$703,544 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Faraz Kerendi of Austin, TX is reported in the CMS Open Payments database as having received $906,136 across 1,199 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $703,544 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71,783 104
2024 General $135,793 168
2023 General $190,455 191
2022 General $185,735 269
2021 General $139,511 191
2020 General $66,730 84
2019 General $116,128 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faraz Kerendi
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Faraz Kerendi were reported at $71,783. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Faraz Kerendi Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $116,128 $886 $178–$3,167 $163
2020 $66,730 $341 $108–$1,605 $114
2021 $139,511 $453 $125–$1,886 $132
2022 $185,735 $695 $180–$2,566 $149
2023 $190,455 $745 $205–$2,662 $160
2024 $135,793 $799 $214–$2,967 $164
2025 $71,783 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $537,055 604 payments
  2. Abbott Laboratories $152,230 199 payments
  3. Medical Device Business Services, Inc. $119,164 92 payments
  4. Ethicon US, LLC $49,911 43 payments
  5. Medtronic, Inc. $16,467 120 payments
  6. Ethicon Inc. $9,838 7 payments
  7. Medtronic Vascular, Inc. $9,659 38 payments
  8. Edwards Lifesciences Corporation $3,750 20 payments
  9. LivaNova USA, Inc. $1,949 9 payments
  10. Aziyo Biologics, Inc. $890 8 payments
  11. Other $5,221 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $715,664 273 payments
  2. Travel and Lodging $149,958 420 payments
  3. Food and Beverage $35,458 502 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 2 payments
  5. Education $56 2 payments
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $282,178 312 payments
  2. SURGICEL NU-KNIT $161,402 76 payments
  3. EVARREST $154,558 75 payments
  4. ETHICON $143,289 76 payments
  5. ATRICLIP LAA EXCLUSION SYSTEM $134,357 172 payments
  6. SURGIFLO Hemostatic Matrix $132,436 64 payments
  7. SYNERGY ABLATION SYSTEM $92,460 105 payments
  8. EPI-SENSE GUIDED COAGULATION SYS $58,838 51 payments
  9. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS $42,128 34 payments
  10. VISTASEAL $25,745 29 payments
  11. Other $78,925 365 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$268,360

Medicare's payments for the services billed

Medicare patients

238

Average age 76

Services billed

596

95 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 69%
Atrial fibrillation 67%
Arthritis 50%
Chronic kidney disease 38%
Diabetes 37%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record